Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Queensland Health
Mallinckrodt
US Department of Justice
Fuji
Boehringer Ingelheim

Generated: March 24, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INSULIN ZINC SUSP PROMPT BEEF

« Back to Dashboard

Clinical Trials for Insulin Zinc Susp Prompt Beef

Trial ID Title Status Sponsor Phase Summary
NCT00467246 Sub-Cutaneous Insulin in Hyperglycaemic Emergencies Withdrawn The Royal Bournemouth Hospital N/A Hyperglycaemic emergencies are associated with significant mortality (mortality in Diabetic Ketoacidosis 0.65 - 3.3% and in HyperOsmolar Non-Ketotic Coma 12 -17%). To reduce morbidity and mortality, prompt intervention and coma and close monitoring are essential. The study is designed to investigate whether a simple intervention with a long acting insulin can improve resolution of acidosis and hyperglycaemia, prevent recurrence of ketoacidosis and shorten hospital stay.
NCT00657280 Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure Completed Merck Sharp & Dohme Corp. Phase 0 This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart.
NCT00657280 Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure Completed Stanford University Phase 0 This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart.
NCT01016509 Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis Completed Second University of Naples N/A A multicentric study will evaluate whether peri-procedural tight glycemic control during angioplasty revascularization for acute coronary syndrome (ACS) reduces circulating inflammatory cytokines and thrombus formation in hyperglycaemic patients. Moreover, the investigators will assess whether the tight glycemic control during the first month from coronary event reduces the incidence of coronary stent restenosis at 6-months from PCI.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Insulin Zinc Susp Prompt Beef

Condition Name

Condition Name for Insulin Zinc Susp Prompt Beef
Intervention Trials
Insulin Resistance 2
Heart Failure, Congestive 1
Diabetes Mellitus 1
Type 2 Diabetes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Insulin Zinc Susp Prompt Beef
Intervention Trials
Insulin Resistance 2
Diabetes Mellitus 2
Hyperinsulinism 1
Congenital Hyperinsulinism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Insulin Zinc Susp Prompt Beef

Trials by Country

Trials by Country for Insulin Zinc Susp Prompt Beef
Location Trials
United States 3
Israel 1
Italy 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Insulin Zinc Susp Prompt Beef
Location Trials
District of Columbia 1
New York 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Insulin Zinc Susp Prompt Beef

Clinical Trial Phase

Clinical Trial Phase for Insulin Zinc Susp Prompt Beef
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Insulin Zinc Susp Prompt Beef
Clinical Trial Phase Trials
Unknown status 3
Completed 2
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Insulin Zinc Susp Prompt Beef

Sponsor Name

Sponsor Name for Insulin Zinc Susp Prompt Beef
Sponsor Trials
National Institute for Health Research, United Kingdom 1
George Washington University 1
Sheba Medical Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Insulin Zinc Susp Prompt Beef
Sponsor Trials
Other 9
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Medtronic
Cantor Fitzgerald
Chubb
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.